Hudson Therapeutics announced positive results from Part 1 of its Phase 2b trial of Nugel for atopic dermatitis, with the Safety Monitoring Committee recommending advancement to Part 2.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.